EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Sodium-Glucose Cotransporter 2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease

Marie Therese Bou Antoun iD, Abdul Hamid Borghol, Levon Souvalian iD, Mohamad Hadla iD, Georges Abboud iD, Ahmad Ghanem iD, Fadi George Munairdjy Debeh iD, Jean Marc Mardirossian iD, Mahdi Salih iD, Pranav S Garimella iD, Volker Vallon iD, Fouad T Chebib iD

Journal of the American Society of Nephrology · 2026-04 · 37 (4) · 861-880

DOI: 10.1681/asn.0000000943 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 10.11.2025. Verfasst von Marie Therese Bou Antoun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, Florida. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Polycystic Kidney, Autosomal Dominant. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and a leading cause of kidney failure worldwide. Disease progression is driven by cyst expansion, tubular injury, and maladaptive metabolic and hemodynamic changes. Tolvaptan remains the only US Food and Drug Administration–approved disease-modifying therapy, however its tolerability and safety profile highlight the need for additional strategies. Sodium-glucose cotransporter 2 inhibitors (SGLT2is), initially developed for glycemic control, have demonstrated robust kidney-protective and cardioprotective effects across diverse patient populations, including those without diabetes. By lowering intraglomerular pressure, metabolic reprogramming, and attenuating hypoxic microenvironment and inflammation, SGLT2is target mechanisms that are relevant to ADPKD. However, concerns that SGLT2i may provoke osmotic diuresis and activate vasopressin led to systematic exclusion of patients with ADPKD from pivotal outcome trials. The 2025 Kidney Disease Improving Global Outcomes ADPKD guidelines explicitly advise against the use of SGLT2i for slowing kidney function decline in ADPKD. In this review, we examine mechanistic intersections between SGLT2i and ADPKD pathophysiology, summarize available preclinical and early clinical data, and discuss ongoing large trials designed to address safety and efficacy of SGLT2i in patients with ADPKD. We also highlight the importance of genetic heterogeneity, as most ongoing trials are enriched for rapid progressors carrying PKD1 or PKD2 pathogenic variants, while other genotypes such as DNAJB11 , ALG8 , and ALG9 , often associated with greater interstitial fibrosis, are underrepresented. Substratification of patients by genotype, risk of progression, and comorbidities will be essential to guide precision application of SGLT2i. Whether SGLT2i can ultimately be positioned as an adjunctive or standalone therapy for ADPKD remains unresolved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsPolycystic Kidney, Autosomal DominantHumansTolvaptan

Stichwörter der Autor:innen

ADPKDCKDESKDSGLT2 inhibitorschronic inflammationclinical trialdrug metabolismglomerular hyperfiltrationpolycystic kidney diseaserenal fibrosis

Substanzen

Sodium-Glucose Transporter 2 InhibitorsTolvaptan

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, Florida.
  • Mayo Clinic Florida PKD Center of Excellence, Jacksonville, Florida.
  • Department of Internal Medicine, Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Division of Nephrology-Hypertension, University of California, La Jolla, California.
  • Department of Pharmacology, University of California, La Jolla, California.
  • VA San Diego Healthcare System, San Diego, California.

ORCID-Profile: Marie Therese Bou Antoun, Levon Souvalian, Mohamad Hadla, Georges Abboud, Ahmad Ghanem, Fadi George Munairdjy Debeh, Jean Marc Mardirossian, Mahdi Salih, Pranav S Garimella, Volker Vallon, Fouad T Chebib

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health

Zitieren

APA

Bou Antoun, M. T., Borghol, A. H., Souvalian, L., Hadla, M., Abboud, G., Ghanem, A., Munairdjy Debeh, F. G., Mardirossian, J. M., Salih, M., Garimella, P. S., Vallon, V., & Chebib, F. T. (2026). Sodium-Glucose Cotransporter 2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology, 37(4), 861-880. https://doi.org/10.1681/asn.0000000943

Vancouver

Bou Antoun MT, Borghol AH, Souvalian L, Hadla M, Abboud G, Ghanem A, et al. Sodium-Glucose Cotransporter 2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology. 2026;37(4):861-880. doi:10.1681/asn.0000000943

BibTeX
@article{BouAntoun2026,
  author = {Bou Antoun, Marie Therese and Borghol, Abdul Hamid and Souvalian, Levon and Hadla, Mohamad and Abboud, Georges and Ghanem, Ahmad and Munairdjy Debeh, Fadi George and Mardirossian, Jean Marc and Salih, Mahdi and Garimella, Pranav S and Vallon, Volker and Chebib, Fouad T},
  title = {Sodium-Glucose Cotransporter 2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  volume = {37},
  number = {4},
  pages = {861--880},
  doi = {10.1681/asn.0000000943}
}
Kostenlos starten →